Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/183714
Title: Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
Author: Galindo, Ruth
Sánchez-López, E. (Elena)
Gómara Elena, María José
Espina García, Marta
Ettcheto Arriola, Miren
Cano Fernández, Amanda
Haro Villar, Isabel
Camins Espuny, Antoni
García López, María Luisa
Keywords: Farmacologia ocular
Pèptids
Nanopartícules
Agents antiinflamatoris
Ocular pharmacology
Peptides
Nanoparticles
Antiinflammatory agents
Issue Date: 26-Jan-2022
Publisher: MDPI
Abstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release was carried out. Ocular tolerance of the formulations was ensured in vitro and in vivo and anti-inflammatory therapeutic efficacy was also assessed. Surface functionalized nanoparticles loading Licochalcone-A were developed with an average size below 200 nm, a positive surface charge, and a monodisperse population. The formulations were non-irritant and showed a prolonged Licochalcone-A release. Despite the fact that both Licochalcone-A Tet-1 and B6 functionalized nanoparticles demonstrated to be suitable for the treatment of ocular inflammation, B6 targeted nanoparticles provided greater therapeutic efficacy in in vivo assays. Keywords: Licochalcone-A; nanoparticles; ocular inflammation; cell-penetrating peptides; PLGA
Note: Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics14020285
It is part of: Pharmaceutics, 2022, vol. 14, p. 285
URI: http://hdl.handle.net/2445/183714
Related resource: https://doi.org/10.3390/pharmaceutics14020285
ISSN: 1999-4923
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
717860.pdf3.37 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons